-
Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide
in PRESS RELEASE 2017 onFerring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with…
0 -
Ferring highlights progress on social and environmental goals in Corporate Social Responsibility (CSR) Review 2015-2016
in PRESS RELEASE 2017 onFerring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals…
-
Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer
in PRESS RELEASE 2017 onFerring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer…
-
Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada
in PRESS RELEASE 2017 onFerring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing…
-
Waking up to go to the toilet is the number one cause of a poor night’s sleep, say experts on World Sleep Day
in PRESS RELEASE 2017 onOn World Sleep Day sleep experts encourage people to understand the value of healthy and solid sleep…
-
Ferring collaborates with ICF on development of a potential new treatment for anal fissures with a focus on improving quality of care for IBD patients
in PRESS RELEASE 2017 onFerring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research…
-
Ferring acquires ex-U.S. assets and rights for Vitaros® (alprostadil cream), Apricus’ on-demand topical cream for erectile dysfunction
in PRESS RELEASE 2017 onFerring Pharmaceuticals today announced an agreement with Apricus Biosciences, Inc. (Nasdaq:APRI), granting Ferring global…
-
Ferring Announces Recipients of Innovation Grants Program 2016-2017
in PRESS RELEASE 2017 onFerring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute…
-
Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
in PRESS RELEASE 2017 onFerring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive…
-
Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
in PRESS RELEASE 2017 onFerring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered…
PRESS RELEASE 2017
PRESS RELEASE 2017